Related Experiment Video

Updated: May 16, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.3K

Obesity and heart failure-the role of GLP-1 receptor agonists

Gregor Simonis1, Ulrike Schatz2

  • 1Kardiologische Ambulanz und Herzkatheterlabor, MVZ Praxisklinik Herz und Gefäße, Forststraße 3, 01099, Dresden, Germany. gregor.simonis@praxisklinik-dresden.de.

Herz
|April 2, 2025
PubMed

Insights

Glucagon-like peptide‑1 (GLP-1) receptor agonists and tirzepatide show promise for managing obesity-driven heart failure with preserved ejection fraction (HFpEF). These therapies may improve symptoms and outcomes in patients with HFpEF, regardless of diabetes status.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Obesity is a significant driver of heart failure with preserved ejection fraction (HFpEF), causing various pathophysiological changes.
  • Standard treatments like diuretics, SGLT2 inhibitors, and mineralocorticoid antagonists may not fully alleviate symptoms in these patients.
  • Understanding novel therapeutic targets is crucial for improving HFpEF management.

Purpose of the Study:

  • To review current evidence on GLP-1 receptor agonists and tirzepatide in obesity-driven HFpEF.
  • To evaluate the efficacy of these agents in improving symptoms and clinical outcomes.
  • To assess their utility in patients with and without diabetes.

Main Methods:

  • Literature review of clinical studies and trials.
  • Analysis of data on patient symptoms and adverse events.
  • Examination of outcomes related to HFpEF in the context of obesity and diabetes.

Main Results:

  • GLP-1 receptor agonists and tirzepatide demonstrate potential benefits in managing HFpEF symptoms driven by obesity.
  • These agents may offer improved cardiovascular outcomes in affected patient populations.
  • Evidence suggests efficacy irrespective of comorbid diabetes status.

Conclusions:

  • GLP-1 receptor agonists and tirzepatide represent a promising therapeutic avenue for obesity-related HFpEF.
  • Further research is warranted to fully elucidate their long-term benefits and optimal use.
  • These agents could become valuable additions to the treatment of HFpEF in obese individuals.

Keywords:
Body weightDiabetesHeart failure, preserved ejection fractionSemaglutideTirzepatide

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.6K
Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
143
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
128
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
10.9K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140